Around Fairweather Image
Home Page > Publications & Presentations

 

Publications & presentations

. 2012  . 2011

 

 

 

2012

 

Publications

 

  1. Zugna D, Geskus RB, de Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M, Babiker A and Porter K for the CASCADE Collaboration in EuroCoord. Differences in time to virological failure, treatment change and interruption, between persons treated within 12 months of HIV seroconversion and in chronic infection. Antiviral Therapy 2012 (in press).
  2. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS ONE 2012 (in press).
  3. de Wolf F, Sabin C, Kirk O, Thorne C, Chene G, Porter K for EuroCoord. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clinical Investigations 2012 (in press).
  4. Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, Del Amo J; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis. 2012 Jan;54(1):111-8. [Pubmed]
  5. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, Monforte A, Phillips A, Lundgren J and Kirk O for the EuroSIDA study group. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012 Jan 28;26(3):315-323. [Pubmed]

 

 

Conference presentations

 

  1. Ashley Olson, Laurence Meyer, Maria Prins, Rodolphe Thiebaut, Marguerite Guiguet, Marie-Laure Chaix, Pauli Amornkul, Abdel Babiker and Kholoud Porter for CASCADE Collaboration in EuroCoord. Proportion of HIV elite controllers and loss of elite status according to two commonly used definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US.
  2. Sara Lodi, Martin Fisher, Andrew Phillips, Andrea De Luca, Jade Ghosn, Ruslan Malyuta, Robert Zangerle, Santiago Moreno, Kholoud Porter for CASCADE Collaboration in EuroCoord. Identification of severe primary HIV infection through clinical, immunological and virological definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US.
  3.  Van der Helm J on behalf of the CASCADE collaboration. Effect of hepatitis C coinfection on cause-specific mortality following HIV seroconversion in the pre-cART and cART eras. 47th annual meeting of the European Association for the Study of Liver (EASL), Barcelona, Spain, April 2012.

 

 

 

2011

 

Publications

 

  1. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE)* in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared to the general population: evidence from a large European observational cohort collaboration. Int. J. Epidemiol. Advance Access published November 28, 2011; doi: 10.1093/ije/dyr164. [article]
  2. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord (Judd A, Penazzato M, Townsend C, Duong T, Castro H, Goetghebuer T, Warszawski J, Galli L, Chiappini E, de Martino M, Ene L, Giaquinto C, Königs C, LeChenadec J, Lyall H, Noguera Julian A, Ramos JT, Rojo-Conejo P, Rudin C, Thorne C, Tookey P, Tudor-Williams G, Gibb DM). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS 2011 Nov 28;25:2279-2287. [PubMed]
  3. Reekie J, Gatell J, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska J, Mocroft A, for the EuroSIDA in EuroCoord. Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS. 2011 Nov 28;25:2259-68. [PubMed]
  4. Cozzi-Lepri A, Prosperi MCF, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies. Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS One. 2011 Nov 16; 6(11): e25665.[Epub ahead of print]
  5. Nakagawa F for the PLATO II group for COHERE in EuroCoord. Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. JAIDS 2011 Nov 11. [Epub ahead of print]
  6. Soriano V, Grint D, Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011 Oct 23:25:1987-92. [PubMed]
  7. The Pursuing Later Treatment Option II (PLATO II) project team* for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group*. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases. 2011 Oct 7. [Epub ahead of print]
  8. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, del Amo J, Johnson A M, Babiker A, Porter K on behalf of the CASCADE Collaboration in EuroCoord. Time from HIV seroconversion to reaching CD4 thresholds <200, <350 and <500 cells/mm3; assessment of need following changes in treatment guidelines. Clin Infec Dis 2011 Oct;53:817-825. [PubMed]
  9. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011 Sep 26;171:1560-9. [Pubmed]
  10. Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J, the EuroSIDA study group. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis. 2011 Sep 1;204:741-52. [PubMed]
  11. Cozzi-Lepri A, Paredes R, Phillips AN, Clotet B, Kjær J, Von Wyl V, Kronborg G, Castagna A, Bogner JR and Lundgren JD for EuroSIDA in EuroCoord. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*). HIV Med 2011 Aug 17; 2012 Jan;13:62-72. [Pubmed]
  12. Thorne C, Semenenko I, Malyuta R; for the Ukraine European Collaborative Study Group in EuroCoord. Prevention of mother-to-child transmission of HIV among pregnant women using injecting drugs in Ukraine, 2000-2010. Addiction 2012 Jan;107:118-28. [Pubmed]
  13. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. AIDS 2011 Jul 31;25:1505-1513. [PubMed]
  14. Jaffe H, De Stavola B, Carpenter L, Porter K and Cox D. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011 Jul 17;25:1395-1403. [PubMed] 
  15. European Collaborative Study in EuroCoord, Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther. 2011 Jul 8;16:895-903. [PubMed]
  16. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A for the EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011 Jun 19;25:1305-1315. [PubMed]
  17. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. Blood 2011 Jun 9;117:6100-8. [PubMed]
  18. Fox ZV, Cozzi-Lepri A, d'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD for EuroSIDA. Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. Antiviral Therapy. 2011 May 17;16:781-5. [PubMed]
  19. Van der Helm J, Prins M, Del Amo J, Bucher H, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R. The hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. AIDS 2011 May 15; 25:1083-1091. [PubMed]
  20. Mussini C,  Cossarizza A, Sabin C,  Babiker A, De Luca A, Bucher H, Fisher M, Rezza G, Porter K, Dorrucci M. Decline of CD4+ T cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. AIDS 2011 May 15; 25:1041-104. [PubMed]
  21. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011 May 7; 377:1580-1587. [PubMed]
  22. Wittkop L, Günthard H, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011 May; 11:363-371. [PubMed] 
  23. The PENPACT-1 (PENTA 9 / PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infectious Diseases. 2011 Apr; 11: 273-283. [PubMed]
  24. Bannister W, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A,  Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; the EuroSIDA study group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011 Apr; 66:901-11. [PubMed]
  25. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; for the EuroSIDA study group. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. HIV Clin Trials 2011 Mar-Apr; 12:109-17. [PubMed]
  26. Bakoyannis G, Touloumi G. Practical methods for competing risks data: A review. Stat Methods Med Res 2011 Jan 7. [Epub ahead of print]

 


Conference presentations

 

  1. Soriano V on behalf of the EuroSIDA study. Hepatitis delta in HIV-infected individuals in Europe. 13th European AIDS Conference/EACS, Belgrade, October 2011. 
  2. Søgaard on behalf of the EuroSIDA study. The incidence of serious non-AIDS defining infections in the EuroSIDA cohort. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  3. Peters L on behalf of the EuroSIDA study. Chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) in HIV-infected patients in the EuroSIDA study. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  4. Grint D, A Phillips on behalf of the EuroSIDA study.  Predictors of hepatitis C viremia in co-infected individuals. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  5. Thorne C, Vigano A, Goetghebuer T, Alam N for the European Paediatric HIV and Lipodystrophy Study in EuroCoord. Components of metabolic syndrome in young adults with life-long HIV. 17-20 July 2011 IAS, Rome, Italy [Abstract]
  6. Podlekareva DN, Grint D, Panteleev A, Rakhmanova A, Miller R, Bruyand M, Furrer H, Post F, Zeltina I, Skrahin A, Miro JM, Obel N, Girardi E, Losso MH, Toibaro J, Caylá J, Lundgren JD, Kirk O, HIV/TB Collaboration Study Group. Mortality Rate, TB Recurrence and Causes of Death in HIV/TB Coinfected Patients: Results from the HIV/TB Collaborative Study. 13th European AIDS Conference/EACS, Belgrade, October 2011. [Presentation]
  7. Malyuta R, Semenenko I, Azhischeva H, Peters H, Thorne C for the Ukraine Paediatric HIV Cohort Study in EuroCoord. Children living with HIV in Ukraine: establishing a new paediatric cohort study. 3rd International Workshop on HIV Pediatrics, 17-20 July 2011 IAS, Rome, Italy [Abstract]
  8. Lodi S, d’Arminio Monforte A, del Amo J, Abgrall S, Sabin C, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. 17-20 July 2011 IAS, Rome, Italy [Abstract]
  9. Huang X, Lodi S, Fox Z, Phillips A, Johnson A, Porter K, Xu X and Wu H on behalf of the Beijin PRIMO cohort study and the CASCADE collaboration. Patterns of decrease in CD4 cell count after seroconversion: Comparison between Beijing PRIMO cohort and CASCADE seroconverter cohorts. 17-20 July 2011 IAS, Rome, Italy [Abstract]
  10. Judd A, Ene L, Goetghebuer T, Noguera A, Ramos JT, Thorne C, Duong T, Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord. Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing post-marketing surveillance study. 15-16 July 2011 IAS, Rome, Italy [Abstract]
  11. Compagnucci A on behalf of the PENTA Steering Committee. Long term consequences of planned treatment interruptions in HIV infected children: Results from the TICCH (Treatment Interruption in Children with Chronic HIV-Infection) /PENTA 11 trial. 3rd HIV Paediatric Workshop Rome 15-16 July 2011. Published in Reviews in Antiviral Therapy & Infectious Diseases 2011; 8: Abstract no. O_10, p.12. [Abstract]
  12. Heiner C. Bucher on behalf of the OI working group of COHERE. Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected patients with sustained viral response to cART. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Presentation]
  13. Van der Helm J, Prins M, del Amo J, Bucher H C, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R B, on behalf of the CASCADE collaboration. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. International Liver Congress 30 March- 3 April 2011 EASL, Berlin, Germany [Abstract]
  14. Touloumi G, Pantazis N, Chaix M L, Meyer L, Thiébaut R, Masquelier B, Kücherer C, d’Arminio Monforte A, Lodi S, Porter K, and CASCADE. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. 27 Feb- 2 March 2011 CROI, Boston.
  15. Smit C, d'Arminio A, de Wolf F, Puoti M, Dabis F on behalf of the HCV working group of COHERE. HCV Treatment and CD4 Cell Count Decline in HIV/HCV Co-infected Patients: European Cohort Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Poster]
  16. Kowalska JD, Mocroft A, Reekie J, Phillips A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Lundgren JD and Kirk O for the EuroSIDA study group. Risk of Cause-specific Deaths over Calendar Time and according to Cumulative Exposure to Combination Antiretroviral Therapy (cART). 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Poster]
  17. Cozzi-Lepri A, Paredes R, Phillips A, Kjær J, Lazzarin A, van Lunzen J, Karlsson A, Johnson M, and Lundgren J for the EuroSIDA study group. Predictors of Virologic Response to Etravirine-based cART Regimens in a Large European Cohort of HIV-infected Patients. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Poster]

 

| Home Page | Site Map | Search | FAQ | Feedback | List Access Keys |